Premium
Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood–brain and blood–ocular barriers
Author(s) -
Miller Donald W.,
Hinton Martha,
Chen Fang
Publication year - 2011
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.21110
Subject(s) - efflux , p glycoprotein , pharmacology , transporter , medicine , blood–brain barrier , abcg2 , permeability (electromagnetism) , multidrug resistance associated protein 2 , chemistry , endocrinology , membrane , multiple drug resistance , atp binding cassette transporter , biochemistry , central nervous system , gene , antibiotics
Abstract Aims The objective of the present study was to evaluate drug efflux transporter interactions of darifenacin and examine the impact of such transporter interactions on darifenacin permeability in an in vitro model of the blood–brain barrier (BBB) and blood–ocular barrier (BOB). Methods Cell membranes expressing human P‐glycoprotein (P‐gp), multidrug resistance‐associated protein (MRP), and breast cancer resistance protein (BCRP) were examined for ATPase activity following darifenacin exposure (0–10 µM). Primary cultured bovine brain microvessel endothelial cells (BBMEC) and P‐gp transfected Manin–Darby canine kidney epithelial cells (MDCK MDR1 ) were used to examine darifenacin permeability and drug efflux transporter responses. Results Concentration‐dependent increases in ATPase activity was observed in P‐gp membranes following darifenacin exposure. Both MRP and BCRP membrane preparations were unresponsive to darifenacin. Studies in both BBMEC and MDCK MDR1 monolayers confirmed a P‐gp interaction for darifenacin and significantly greater efflux (basolateral to apical) permeability for darifenacin that was reduced by the P‐gp inhibitor, elacridar. Conclusions Darifenacin is a substrate for the P‐gp drug efflux transporter present in both BBB and BOB. The P‐gp drug efflux transporter liabilities of darifenacin may limit its penetration into brain and ocular tissue thereby reducing side effect potential. Neurourol. Urodynam. Neurourol. Urodynam. 30: 1633–1638, 2011. © 2011 Wiley Periodicals, Inc.